Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 8, 2020
- Accepted in final form April 29, 2020
- First Published June 2, 2020.
Author Disclosures
- Desiree De Simoni, MD,
- Gerda Ricken, MSc,
- Michael Winklehner, MD,
- Inga Koneczny, PhD,
- Michael Karenfort, MD,
- Ulf Hustedt, MD,
- Ulrich Seidel, MD,
- Omar Abdel-Mannan, MD,
- Pinki Munot, MD,
- Simon Rinaldi, MD,
- Claudia Steen, MD,
- Michael Freilinger, MD,
- Markus Breu, MD,
- Rainer Seidl, MD,
- Markus Reindl, PhD,
- Julia Wanschitz, MD,
- Cinta Lleixà, PhD,
- Günther Bernert, MD,
- Klaus-Peter Wandinger, MD, PhD,
- Ralf Junker, MD,
- Luis Querol, MD, PhD,
- Frank Leypoldt, MD, PhD,
- Kevin Rostásy, MD* and
- Romana Höftberger, MD*
- Desiree De Simoni, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gerda Ricken, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Winklehner, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Inga Koneczny, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am funded by a Hertha Firnberg project grant by the Austrian Science Find (FWF). Project Grant Nr. T996-B30
NONE
I am funded by a Hertha Firnberg project grant by the Austrian Science Find (FWF). Project Grant Nr. T996-B30
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Karenfort, MD,
NONE
NONE
Speaker Honorar from Novartis Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ulf Hustedt, MD,
(1) Allergan an IPSEN
NONE
Travel and speaker honoraria from Allergan, Ipsen, Braun and UCB pharma
Pädiatrische Praxis, 2020, Issue 6 in press
NONE
NONE
CEO, med+ED, Agency for Medical Education 2005 until now
NONE
NONE
NONE
NONE
Technical grant from EMS for shock wave therapy in childhood
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ulrich Seidel, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Omar Abdel-Mannan, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pinki Munot, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Simon Rinaldi, MD,
1. GAIN patient charity medical advisory board (unpaid) 2. ABN research council member (unpaid) 3. Inflammatory Neuropathy Consortium board member (unpaid)
NONE
1. Fresenius, travel to conference 2. Alnylam, speaker honorarium
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Medical Research Council (UK), MR/P008399/1, Clinician Scientist Fellowship (PI), 4 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claudia Steen, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Freilinger, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Markus Breu, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rainer Seidl, MD,
1) Austrian Fingolimod Advisory Board 1/2019
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Markus Reindl, PhD,
NONE
NONE
NONE
PLOS ONE, academic editor, 2012,
NONE
NONE
NONE
NONE
NONE
The University Hospital and Medical University of Innsbruck (Austria, Markus Reindl) receive payments for antibody assays (NMDAR, AQP4 and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Luebeck, Germany).
NONE
Euroimmun AG, Germany
(1) Austrian Science Funds (FWF), project P32699, PI, 2019-2022 (2) Austrian Federal Ministry of Science, Research and Education, grant BIG WIG MS, PI, 2013-2017 (3) Austrian Research promotion Agency (FFG), Bridge 1 project Nr. 853209, PI, 2016-2018 (4) Austrian Science Funds (FWF), project W1206, PI, 2007-2018 (5), Austrian Science Funds (FWF), project ZFP326990, PI, 2019-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Julia Wanschitz, MD,
NONE
NONE
Speaker honoraria from Sanofi-Genzyme and Takeda (Shire Austria GmbH)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The GBS/CIDP Foundation International
NONE
NONE
NONE
NONE
NONE
NONE
- Cinta Lleixà, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Günther Bernert, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klaus-Peter Wandinger, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf Junker, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luis Querol, MD, PhD,
Commercial entity: Sanofi-Genzyme, CSL Bering, Novartis, UCB Pharma, Johnson and Johnson, Alexion, Annexon
NONE
Commercial: CSL Behring, Novartis and Biogen, travel grant
Editorial Board Member of the European Journal of Neurology
NONE
NONE
NONE
NONE
Commercial: CSL Behring, Roche, Sanofi, Grifols, Merck
NONE
NONE
NONE
(1) Fondo de Investigaciones Sanitarias, PI16/000627 (2) SLT006/17/00131 of the Pla estratègic de Recerca i Innovació en Salut (PERIS), Departament de Salut, Generalitat de Catalunya
NONE
GBS-CIDP Foundation International (
NONE
NONE
NONE
NONE
NONE
NONE
- Frank Leypoldt, MD, PhD,
(1) Roche, Biogen, Alexion
NONE
(1) Grifols (2) Teva (3) Biogen (4) Fresenius (5) Bayer (6) Novartis (6) Roche (6) Novartis (7) Merck (8) Roche (9) Alexion
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Institute of Laboratory Medicine, University Hospital Schleswig- Holstein Campus Kiel, Germany, commercial antibody testing service, 20%
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kevin Rostásy, MD* and
Scientific adviser on Fingolimod project-Novartis
NONE
Advisory Board Meeting Novartis and Merck 2017, 2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Romana Höftberger, MD*
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Division of Neuropathology and Neurochemistry (D.D.S., G.R., M.W., I.K., R.H.), Department of Neurology, Medical University of Vienna, Austria; Department of Neurology (D.D.S.), University Hospital St. Poelten, Austria; Department of General Pediatrics, Neonatology and Pediatric Cardiology (M.K.), University Children's Hospital, Heinrich Heine University Duesseldorf, Germany; Department of Neuropediatric Rehabilitation (U.H.), Vamed Clinic Hattingen, Germany; Department of Neuropediatrics (U.S.), Charité University, Berlin, Germany; Paediatric Neurology (O.A.-M.), Great Ormond Street Hospital for Children, London, United Kingdom; Dubowitz Neuromuscular Centre (P.M.), Great Ormond Street Hospital for Children, London, United Kingdom; Nuffield Department of Clinical Neurosciences (S.R.), University of Oxford and Oxford University Hospitals NHS Foundation Trust; Department of Paediatric and Adolescent Medicine (C.S.), St Joseph Hospital, Berlin, Germany; Department of Pediatrics and Adolescent Medicine (M.F., M.B., R.S.), Medical University of Vienna, Austria; Department of Neurology (M.R., J.W.), Medical University of Innsbruck, Austria; Neuromuscular Diseases Unit (C.L., L.Q.), Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Spain; SMZ Süd (G.B.), Kaiser-Franz Josef Hospital with Gottfried von Preyer Children Hospital, Vienna, Austria; Institute of Clinical Chemistry (K.-P.W., R.J., F.L.), University Hospital Schleswig-Holstein, Kiel/Lübeck, Germany; Department of Neurology (F.L.), University Hospital Schleswig-Holstein, Kiel, Germany; and Department of Pediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany.
- Correspondence
Dr. Rostásy k.rostasy{at}kinderklinik-datteln.de or Dr. Höftberger romana.hoeftberger{at}meduniwien.ac.at
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.